Pembrolizumab, Eftilagimod alfa
Phase 2Active 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoadjuvant
Conditions
Neoadjuvant, Immunotherapy, Sarcoma,Soft Tissue, Radiation Therapy
Trial Timeline
Jul 17, 2023 → Apr 30, 2027
NCT ID
NCT06128863About Pembrolizumab, Eftilagimod alfa
Pembrolizumab, Eftilagimod alfa is a phase 2 stage product being developed by Immutep for Neoadjuvant. The current trial status is active. This product is registered under clinical trial identifier NCT06128863. Target conditions include Neoadjuvant, Immunotherapy, Sarcoma,Soft Tissue.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06128863 | Phase 2 | Active |
Competing Products
4 competing products in Neoadjuvant
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR-A1811 + Trastuzumab Emtansine | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Fluorouracile + Epirubicin + Cyclophosphamide + Letrozole + Palbociclib | Pfizer | Phase 2 | 51 |
| Zanzalintinib | Exelixis | Phase 2 | 49 |
| E7046 + capecitabine + folinic acid/5-FU/oxaliplatin (mFOLFOX-6) | Adlai Nortye | Phase 1 | 25 |
Other Products from Immutep
eftilagimod alpha + PaclitaxelPhase 2/3
57
Eftilagimod Alfa (Efti) + Docetaxel-cyclophosphamide (TC) intravenous (i.v) + Dose dense Adriamycin-cyclophosphamide (AC) i.vPhase 2
44
IMP321 (eftilagimod alpha) + Placebo + PaclitaxelPhase 2
44
2 vaccine injections in 1 limb + 2 vaccine injections in distinct limbs + 2 "vaccine injections" in distinct limbsPhase 1/2
33
Immunological peptides and immunological adjuvants + HLA-A2 peptides + Montanide ISA51 + IMP321Phase 1/2
33